Taysha Gene Therapies
TSHA
196 hedge funds and large institutions have $1.48B invested in Taysha Gene Therapies in 2025 Q4 according to their latest regulatory filings, with 65 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 22 closing their positions.
231% more call options, than puts
Call options by funds: $7.02M | Put options by funds: $2.12M
195% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 22
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 46
32% more capital inflows, than outflows
Capital inflows: $207M | Capital outflows: $157M
26% more funds holding
Funds holding: 155 → 196 (+41)
1.19% more ownership
Funds ownership: 97% → 98.2% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
+$40.1M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$18.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.3M |
| 4 |
Polar Capital Holdings
London,
United Kingdom
|
+$12.8M |
| 5 |
BlackRock
New York
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
-$38.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.8M |
| 3 |
Deerfield Management
New York
|
-$12.9M |
| 4 |
Jefferies Financial Group
New York
|
-$10.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.7M |
TSHA Hedge Fund Activity: Q4 2025 in Review
196 of the 8,302 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2025, worth a combined $1.48B — up 71% from $866M a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new TSHA positions and 22 closed out — a net gain of 43 holders — while 62 added to existing stakes and 46 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $40.1M. The largest seller was RTW Investments, cutting an estimated $38.6M.
- 196 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2025, up from 155 in Q3 2025.
- Funds reported $1.48B of Taysha Gene Therapies stock for Q4 2025, up 71% quarter-over-quarter.
- 65 funds opened new Taysha Gene Therapies positions in Q4 2025 and 22 closed out, a net change of +43 holders.
- The largest Taysha Gene Therapies buyer in Q4 2025 was Vestal Point Capital, an estimated $40.1M added.
- The largest Taysha Gene Therapies seller in Q4 2025 was RTW Investments, an estimated $38.6M sold.
Based on aggregated 13F filings for Q4 2025.